Wang Shiying, Herbst Elizabeth B, Mauldin F William, Diakova Galina B, Klibanov Alexander L, Hossack John A
From the *Department of Biomedical Engineering, †Division of Cardiovascular Medicine, Cardiovascular Research Center, and ‡Department of Electrical and Computer Engineering, University of Virginia, Charlottesville, VA.
Invest Radiol. 2016 Dec;51(12):758-766. doi: 10.1097/RLI.0000000000000310.
The objective of this study was to evaluate the minimum microbubble dose for ultrasound molecular imaging to achieve statistically significant detection of angiogenesis in a mouse model.
The preburst minus postburst method was implemented on a Verasonics ultrasound research scanner using a multiframe compounding pulse inversion imaging sequence. Biotinylated lipid (distearoyl phosphatidylcholine-based) microbubbles that were conjugated with antivascular endothelial growth factor 2 (VEGFR2) antibody (MBVEGFR2) or isotype control antibody (MBControl) were injected into mice carrying adenocarcinoma xenografts. Different injection doses ranging from 5 × 10 to 1 × 10 microbubbles per mouse were evaluated to determine the minimum diagnostically effective dose.
The proposed imaging sequence was able to achieve statistically significant detection (P < 0.05, n = 5) of VEGFR2 in tumors with a minimum MBVEGFR2 injection dose of only 5 × 10 microbubbles per mouse (distearoyl phosphatidylcholine at 0.053 ng/g mouse body mass). Nonspecific adhesion of MBControl at the same injection dose was negligible. In addition, the targeted contrast ultrasound signal of MBVEGFR2 decreased with lower microbubble doses, whereas nonspecific adhesion of MBControl increased with higher microbubble doses.
The dose of 5 × 10 microbubbles per animal is now the lowest injection dose on record for ultrasound molecular imaging to achieve statistically significant detection of molecular targets in vivo. Findings in this study provide us with further guidance for future developments of clinically translatable ultrasound molecular imaging applications using a lower dose of microbubbles.
本研究的目的是评估超声分子成像在小鼠模型中实现血管生成的统计学显著检测所需的最小微泡剂量。
在Verasonics超声研究扫描仪上采用多帧复合脉冲反转成像序列实施爆前减爆后方法。将与抗血管内皮生长因子2(VEGFR2)抗体(MBVEGFR2)或同型对照抗体(MBControl)偶联的生物素化脂质(基于二硬脂酰磷脂酰胆碱)微泡注射到携带腺癌异种移植瘤的小鼠体内。评估每只小鼠5×10至1×10微泡的不同注射剂量,以确定最小诊断有效剂量。
所提出的成像序列能够在每只小鼠仅5×10微泡的最小MBVEGFR2注射剂量(二硬脂酰磷脂酰胆碱为0.053 ng/g小鼠体重)下实现肿瘤中VEGFR2的统计学显著检测(P < 0.05,n = 5)。相同注射剂量下MBControl的非特异性粘附可忽略不计。此外,MBVEGFR2的靶向对比超声信号随微泡剂量降低而降低,而MBControl的非特异性粘附随微泡剂量增加而增加。
每只动物5×10微泡的剂量是超声分子成像在体内实现分子靶点统计学显著检测的有记录以来的最低注射剂量。本研究结果为未来使用更低剂量微泡的临床可转化超声分子成像应用的发展提供了进一步指导。